Definium Therapeutics reports strong Phase 3 results, plans NDA filing in H1 2026, but holds due to risks.

Definium Therapeutics announced positive Phase 3 trial results for its drug DT120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD), setting the stage for a New Drug Application (NDA) filing in the first half of 2026. The company has over $1 billion in cash, supporting operations through 2030, and aims for a potential commercial launch in 2027. Despite promising efficacy and regulatory progress, the analyst maintains a Hold rating due to high valuation, patent uncertainties, and competitive and regulatory risks in the emerging psychedelic therapy market.

Following the announcement of positive Phase 3 trial results and plans for a New Drug Application filing by Definium Therapeutics, the stock is currently trading at USD 34.15 on Pluang as of Nov 11, 2026 01:51 WIB. The share price has declined by 3.50% in the past day, with a market capitalization of $4.76 billion. Notably, all recent order activity on Pluang is selling, reflecting cautious investor sentiment despite the promising clinical progress.